Antineoplastic Agents

"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Descriptor ID	D000970
MeSH Number(s)	D27.505.954.248
Concept/Terms	Antineoplastic Agents Antineoplastic Agents Agents, Antineoplastic Antineoplastic Drugs Drugs, Antineoplastic Antineoplastics Chemotherapeutic Anticancer Drug Drug, Chemotherapeutic Anticancer Antitumor Drugs Drugs, Antitumor Cancer Chemotherapy Agents Agents, Cancer Chemotherapy Chemotherapy Agents, Cancer Cancer Chemotherapy Drugs Chemotherapy Drugs, Cancer Drugs, Cancer Chemotherapy Chemotherapeutic Anticancer Agents Agents, Chemotherapeutic Anticancer Anticancer Agents Agents, Anticancer Antitumor Agents Agents, Antitumor

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.

Bar chart showing 771 publications over 31 distinct years, with a maximum of 58 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1997	3	1	4
1998	2	1	3
1999	1	1	2
2000	5	2	7
2001	7	1	8
2002	11	2	13
2003	9	8	17
2004	10	9	19
2005	10	10	20
2006	13	5	18
2007	22	5	27
2008	22	9	31
2009	11	8	19
2010	29	13	42
2011	29	13	42
2012	14	11	25
2013	31	10	41
2014	46	9	55
2015	48	10	58
2016	23	14	37
2017	36	5	41
2018	31	8	39
2019	28	6	34
2020	26	4	30
2021	21	6	27
2022	22	1	23
2023	12	0	12
2024	12	15	27
2025	35	3	38
2026	11	0	11

Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.

Tiwari R, Delossantos J, Ghali ENHK, Chavez LA, Chaudhari VS, Han S, Chauhan SC, Yallapu MM. Biodegradable PCL-PLGA Electrospun Nanofibers for Localized Cancer Therapy. ACS Appl Bio Mater. 2026 May 18; 9(10):4579-4593.

View in: PubMed
Vuong NB, Korolkova OY, Izban MG, Sakwe NI, McIntosh AR, Ball DD, Black PJ, Edwards AD, Ballard BR, Adunyah SE, Sakwe AM. Contribution of Mesenchymal-like and Epithelial Cellular Subsets to Chemotherapy Resistance in Triple-Negative Breast Cancer. Int J Mol Sci. 2026 Mar 31; 27(7).

View in: PubMed
Liu W, Mousa AAK, Dayer G, Hopkins AM, Campbell M, Mao Y, Jiang ZH, Lees SJ, Ramachandran R, Hou J. Urea-based lysophosphatidic acid receptor 1 antagonists as potential migrastatics for triple-negative breast cancer. Bioorg Chem. 2026 07 05; 175:109807.

View in: PubMed
Gutierrez DA, Robles-Escajeda E, Lopez-Saenz JA, Kirken RA, Borrego EA, Betancourt AP, Nair S, Roy S, Varela-Ramirez A, Aguilera RJ. Discovery of Two Novel Pyrazole Derivatives as Anticancer Agents Targeting Tubulin Polymerization and MAPK Signaling Pathways. Oncol Res. 2026; 34(4):14.

View in: PubMed
Rasafar N, Sanchez-Michael LA, Torres A, Andujo LA, Gutierrez DA, Varela-Ramirez A, Aguilera RJ, Noveron JC. Novel anticancer alkyl pyridinium derivative exhibits antiproliferative activity via G0/G1 cell cycle arrest and apoptosis activation in triple-negative breast cancer cells. Bioorg Med Chem. 2026 Jun; 137:118638.

View in: PubMed
Del Valle MM, Colon EM, Kettimuthu K, Maner-Smith K, Olson JJ, Kucheryavykh LY. Window of opportunity study measuring defactinib and avutometinib delivery in glioblastomas. Cancer Chemother Pharmacol. 2026 Mar 06; 96(1).

View in: PubMed
Gonzalez SB, Shivam P, Ball D, Ajisegiri SB, Osi I, Misra S, Mutchler AL, Lindsey ML, Martin PM, Sakwe AM, Nde PN. Bugs as drugs: parasite biomolecules as novel therapeutics against breast cancer. Am J Physiol Cell Physiol. 2026 Apr 01; 330(4):C1067-C1080.

View in: PubMed
Dickinson CF, Potluri A, Bland AM, Flipse SM, Hanna GS, Wagner RT, Robertson KD, Ho TH, Sprague DJ, Hoff GR, Stone RP, Tius MA, Tantillo DJ, Hamann MT. On the Discorhabdins Leading to the Aleutianamine Ring System: A One-Step in Situ Transformation Characterized Through Computational and Experimental Studies and Its Implications on Biosynthesis, Synthesis, and Pharmacology. Angew Chem Int Ed Engl. 2026 Apr 20; 65(17):e7864883.

View in: PubMed
Satti VR, Raza MS, Roshani K, Veeranki KC, Mondal T. Design and Synthesis of Novel Indazole-Sulfonamide Derivatives, Cytotoxicity, and Molecular Docking Insights. Chem Biodivers. 2026 Feb; 23(2):e03697.

View in: PubMed
Walker D, Hall A, Bonwell A, Gordon N, Robinson D, Hollomon MG. FOXO1 Inhibition and FADD Knockdown Have Opposing Effects on Anticancer Drug-Induced Cytotoxicity and p21 Expression in Osteosarcoma Cells. Int J Mol Sci. 2026 Jan 17; 27(2).

View in: PubMed

People

Explore

Similar Concepts

Top Journals